Our physician-editors highlight the most clinically relevant findings from the meeting in Rome.
The biggest story at this year's IAS meeting in Rome was undoubtedly HPTN 052, which proved that treatment reduces the risk for HIV transmission. Although a few attendees cynically commented that they could have predicted these results from previous observational studies and the biology of the disease, the consensus was that these findings provide additional impetus for identifying and treating individuals who are infected with HIV and don't know it. The public health benefits of HIV treatment are now proven to be just as impressive as the personal health benefits.
Given that we've already covered HPTN 052 in our review of the published paper (JW AIDS Clin Care Jul 19 2011), the following report highlights other interesting presentations and…
Authors
DisclosuresConsultant/Advisory BoardGilead Sciences; GlaxoSmithKline/ViiV; Merck; Shionogi
Grant/Research SupportNIH; Gilead Sciences; ViiV
Editorial BoardsUpToDate; Clinical Infectious Diseases
DisclosuresConsultant/Advisory BoardGilead Sciences; GlaxoSmithKline/ViiV; Merck; Shionogi
Grant/Research SupportNIH; Gilead Sciences; ViiV
Editorial BoardsUpToDate; Clinical Infectious Diseases
DisclosuresConsultant / Advisory boardGilead Sciences; ViiV; Merck
RoyaltiesUpToDate, Inc.
Grant / Research supportNIH; Department of Health and Human Services
DisclosuresConsultant / Advisory boardGilead Sciences; ViiV; Merck
RoyaltiesUpToDate, Inc.
Grant / Research supportNIH; Department of Health and Human Services